JPRN-UMIN000000517已完成1 期
Study of combination chemotherapy of CPT-11/S-1 after anthracycline and taxane in recurrent or metastatic breast cancer (JBCRG-M01) - Study of combination chemotherapy of CPT-11/S-1 after anthracycline and taxane in recurrent or metastatic breast cancer (JBCRG-M01)
Japan Breast Cancer Research Group (JBCRG)0 个研究点目标入组 12 人开始时间: 2006年11月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
DLT was grade 4 hematological toxicity and grade 3>= nonhematological toxicities. Recommended dose for phase II were CPT-11 100mg/m2, TS-1 80-120mg/day.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Prior chemotherapy with CPT-11, S-1 Diarrhea No lesion other than bone metastasis Brain metastasis Serious cardiac disease
研究者
相似试验
已完成
1 期
A randomized phase l study on TS-1+CDDP+CPT-11(IPS) therapy for patients with advanced/metastatic gastric cancer(HERBIS-4A) (OGSG 1106)Gastric CancerJPRN-UMIN000006864Osaka Gastroestinal cancer chemotherapy Study Group (OGSG)12
已完成
1 期
Phase I Clinical Study of Combination Therapy with Eribulin and Gemcitabine in Patients with Progressive Recurring Breast Cancer (JBCRG-18Gem)JPRN-UMIN000009612JBCRG (Japan Breast Cancer Research Group)7
已完成
2 期
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and NeckCarcinoma of Head/NeckSquamous Cell CarcinomaNCT00139230Dana-Farber Cancer Institute30
已完成
1 期
Phase I Clinical Study of Combination Therapy with Eribulin and Capecitabine in Patients with Progressive Recurring Breast Cancer(JBCRG-18Cape)JPRN-UMIN000009611JBCRG (Japan Breast Cancer Research Group)9
招募中
1 期
Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsLung CancerPancreas CancerOvary CancerHead and Neck CancerBreast CancerColorectal CancerGastric CancerCervical CancerEsophageal CancerSarcomaLiver CancerNCT05187338Second Affiliated Hospital of Guangzhou Medical University100